H.U. GROUPCORPORATE PROFILE02

H.U. Group Corporate Profile03

TOP MESSAGE
We will continue to take on
the challenge of realizing“Healthcare for You.”For more than 70 years since our founding, we havesupported medical care with a focus on clinical testing.
We are now expanding into healthcare and pursuing
global business development to realize the goal of“Healthcare for You” expressed in our company name.
As a standard-bearer for change in the industry, the H.U.
Group will continue striving to contribute to the future of
medical care and healthcare by sincerely responding topeople’s desire for good health.

Director, Chairman, President and Group CEO
H.U. Group Holdings, Inc.

04

Mission, Vision

History of the H.U. Group1950

MissionVisionWith our deep involvement in human health, we aim
to be a group that contributes to the development ofhealthcare through trust and innovation.

1966
For moredetails on
H.U. Group
Philosophy(Formerly Fujizoki Pharmaceutical)

Started the manufacturing and marketingof pharmaceutical products

Create new value in healthcare and thereby contribute tohuman health and the future of medical care.

Foundation of Fujirebio Inc.

Launch of the firstdiagnostic product

1970

1983

Company name changed to Fujirebio
Listed on the 2nd Section of theTokyo Stock Exchange

1987

Listed on the 1st Section of
the Tokyo Stock Exchange 1989

The Statement of H.U. Group
2000

Divestment ofpharmaceutical division

Foundation of SRL, Inc.
(Formerly Tokyo Special Reference Laboratories)

Company name changed to
SRL, Inc.

1987

1990

Listed on the 2nd Section of theTokyo Stock Exchange

2000

Nihon Stery became a whollyowned subsidiary

2001

Listed on the 1st Section of theTokyo Stock Exchange

Foundation of
Nihon Stery, Inc.

What we hold dear isthe starting point for the creation of a prosperous future.
That is, the health of each and every person.
Because we have been watching over people’s health for many decades,
we are able to change the future of medical careand create new possibilities in healthcare.
We will continue the challenge
to deliver optimal healthcare to each individual.

2005
Establishment of Miraca Holdings, Inc.
(Business integration of Fujirebio and SRL)

Establishment of Fujirebio
Holdings, Inc.

2017

2020

We will move forward, unceasingly.
Healthcare for You
For your health, for your future happiness.

Company name changed to H.U. Group Holdings, Inc.
H.U. Group Corporate Profile

05

ABOUT H.U. GROUP
Overview of Business Segments

LTS

Lab Testing and its
related Services

IVD

In-Vitro
Diagnostics

HS

Healthcarerelated Services

146.7
61.9
28.3

billionyen

Number of Group Companies

12.0%

billionyen

272.9 260.9 237.0
billion yen

billion yen

OverseasJapan

Approx.

Approx.

20 30

Sales ratio bybusiness segment

billionyen
IVD

Consolidated Net Sales

billion yen

HS

LTS

26.1%

61.9%

Please scan for
more details

Financial results for FY2023. The percentage
represents the proportion of consolidated sales.

Number of Employees
Permanent employees

As of March 2024

Patents

Temporary employees

5,295 5,119

Number of patents held

Number of patents(As of April 2024)

applications

613

28

(FY2023)

Please scan for
more details

FY202106

FY2022

FY2023As of March 2024

R&D Costs

11,262

Percentage of Female
Managers

H.U. Group’s Long-Term
Environmental Targets
2050

million
yen

22.2

%

¥
FY2023CO2 (total emissions for Scope 1 and 2)

Net Zero2030

As of March 2024

CO2 (total emissions

CO2 (total emissions

for Scope 1 and 2)

for Scope 3)(base: FY2021)

Percentage of Employees
Taking Parental Leave (Male)

82.5

%

FY20232025
CO2 (total emissions

CO2 (total emissions

for Scope 1 and 2)

for Scope 3)

16.8%(base: FY2021)

10.0%

Redu
ction

internal control evaluation(base: FY2021)

Redu
ction

Total of Japanese group companies subject to

Redu
ction

22.5%

Redu
ction

37.8%

(base: FY2021)

H.U. Group Corporate Profile07

OUR BUSINESS
Through trust and innovation, we offer optimal healthcare
solutions to all those who wish to be healthy.
P09
The H.U. Group is a unique company
that offers both “Lab Testing and

P10

P11

Lab Testing and its
related Services

In-Vitro Diagnostics

Healthcare-related
Services

LTS

IVD

HS

its related Services (LTS)” and “InVitro Diagnostics (IVD)” businesses. In
addition to these businesses, we arealso expanding into the “Healthcarerelated Services (HS)” business andare continuing to challenge ourselvesto provide healthcare catered to theindividual.

Unification of sales and marketing functions
P12

R&D
Research & Development

Unified group sales activities by the controlling sales company
By combining the sales and marketing functions of our main subsidiaries and utilizing the Group’s combined strength, we will
integrate the strengths of a wide range of products and services to offer optimized healthcare solutions to our customers.

08

Controlling sales company

Providing General Testing Services to Medical Institutions for Over a Half Century
LTS

Lab Testing and its related Services

Japan’s Largest Laboratory Testing
Center with a Nationwide Network
We collect specimens from various medical institutions nationwide,from medical offices and clinics to large hospitals, to conduct tests

Please scan for
more details

which could lead to the development of new diagnostic methods.

Global Support for the Researchand Development of Medicine

at our laboratories. One of these is the H.U. Bioness Complex, one

Utilizing expertise and advanced technology developed overof the largest facilities of its kind, which began operating in 2022.

30 years of fully supporting clinical trials and tests, as well as a

The H.U. Bioness Complex achieves high reliability and efficiency

domestic and global network, we offer comprehensive support

by reducing testing time through an automated inspection systemfor clinical trials and research. The precision of the tests, as wellequipped with the latest equipment and AI robots.

as services such as pre-trial setup work, specimen collection andAt the H.U. Group, we are entrusted with hundreds of thousands oftransport, measuring, result reports, and data management,laboratory tests from medical institutions nationwide every day. In theoffered with consistent traceability and are of the highest quality.

clinical testing market in Japan, we boast the top share*. Lab TestingWith regard to in-group coordination with the CRO (Contractand its related services (LTS) business, consisting of various operating

Research Organization), we also offer total support for clinicalcompanies centered on SRL, specializes in “esoteric testing,” suchtrials and research from start to finish.

as genetic and oncology testing, which requires advanced technicalexpertise. LTS business currently does business with many of the large
hospitals in the country. In the field of private healthcare facilities(private hospitals or clinics), we do business with facilities nationwide,
contributing to local healthcare by providing attentive and prompt
services.
* Source: Clinical Laboratory Center Directory 2024, Yano Research Institute Ltd.

Development of Services
Combining Healthcare and ICT
In response to the demand for enhanced local healthcare andpreventive medicine, we are developing new solutions that combine
ICT and various services. In addition to promoting the digitalizationof testing information, we are working to enhance the value of

Initiatives for Advanced Medical Careour services in the LTS business by supporting further utilizationof test results by offering SaaS (Software as a Service) for general

As innovations in personalized medicine continue to advance, testing

practitioners and PHR (Personal Health Record) for consumers in an

technologies in advanced medicine are becoming increasingly

integrated manner.

sophisticated. In addition to companion diagnostics-related tests,

Main company

which are necessary for cancer treatment, we focus on omics analysis,
including whole genome sequencing (WGS) and proteome analysis,

H.U. Group Corporate Profile09

Proven Pioneer and Partner to the Diagnostics Industry
IV D

In-Vitro Diagnostics

Strengthening Our R&D and Promoting a New
Global Strategy with a Tripolar Structure withBases in Japan, the United States, and Europe

Please scan for
more details

obtained in Japan, the United States, and Europe, and it was
successfully launched. We are also working on the development ofblood-based reagents, which are experiencing a growing demand.
We have already developed six markers that are available asOperating under Fujirebio Holdings, subsidiaries located inresearch reagents. Additionally, we are preparing for the regulatory

Japan, the United States, and Europe go beyond company

submission of these blood-based reagents in major countries.

boundaries and promote the new global strategy, delivering in-

In 2022, we acquired ADx NeuroSciences N.V., a Belgian

vitro diagnostics worldwide.

biotech company that has developed biomarkers specifically for

The driving force behind our growth is our research andneurodegenerative diseases such as Alzheimer's. In addition to ourdevelopment (R&D) capabilities. By continually strengthening our

involvement in the development of neurodegenerative disease-

R&D efforts, we strive to commercialize “only one” markers ahead ofrelated markers beyond those for Alzheimer’s disease, we will supply

other companies. With a focus on Japan, we utilize our own platformkey raw materials to global in-vitro diagnostics companies through ato demonstrate the clinical value of these markers. Furthermore,

CDMO business model.

through partnerships with in-vitro diagnostics companies worldwide,
we utilize the CDMO (Contract Development and Manufacturing
Organization) business model to expand our reach globally.

A Global Leader in the Testingfor Neurodegenerative Diseases

10

Developing a Platform
That Shapes Future Testing
Since 1992, we have utilized our proprietary fully automatedchemiluminescent enzyme immunoassay system. This platform has
gained high recognition and has been supporting medical institutions

Since developing and launching a biomarker for early detection

and testing centers for over 30 years. In addition, in 1997, we launchedof the plaques associated with Alzheimer’s disease in 1995, we

a rapid diagnostics kit that does not require a special testing device.

have served as a global leader in testing for neurodegenerative

As the kit provides convenient and quick test results, it serves as

diseases. For over 25 years, we have continued to expand our R&D

a platform for testing infectious diseases such as influenza andefforts and reagent lineup.

COVID-19, and we have been expanding its reagent lineup.

Our initiatives have been strengthened through the 2010 acquisition

In 2022, we acquired Fluxus, Inc., an innovative company located inof Innogenetics N.V. (current Fujirebio Europe N.V.). In the field

Silicon Valley, United States. Together with the company, we have beenof Alzheimer’s disease, we obtained approval for a cerebrospinal

jointly developing a diagnostic platform utilizing ultra-high sensitivity

fluid reagent, which is compatible with our fully automateddetection technology. Building upon the existing platform functions,chemiluminescent enzyme immunoassay system. Approval was

we are developing a platform that shapes future testing.

Main company

One-stop Service Providing Total Support and Assisting Efficient Nursing Care Operations
HS

Please scan for
more details

Healthcare-related Services

Supporting Efficient
Hospital Operation

Providing Safe and Reliable
Nursing Care Equipment

Nihon Stery specializes in in-house sterilization at

At Care’x Inc., we provide bulk rentals of nursing carethe central supply rooms in hospitals and external

equipment, supplying equipment such as wheelchairssterilization at the Sterilization Centers (eight domestic

and nursing beds through designated nursing carecenters). We also offer a range of other services,

equipment rental businesses. In order to support theincluding operating room support, endoscopy room

safety and security of users, we propose and provide

support, medical equipment maintenance andnursing care equipment tailored to each individual’s

inspection, and logistics management and transportationneeds and conduct thorough quality management forservices. By providing total support for important tasks

cleaning, disinfection, and preparation work.

related to hospital administration work, including thesale of medical equipment, supplies, and consumables
related to central supply rooms and operating rooms,
we not only enhance operational efficiency and leverage
economies of scale but also contribute to creating anenvironment where physicians and nurses can focus on
medical treatment.
As a medical partner, we are continuously striving tomeet the diverse needs of rapidly evolving healthcare
institutions. To that end, we focus on human resource
development, quality improvement activities, andbusiness development to form a group of professional
technicians who can respond to the latest medical
needs and provide highly specialized technical skills andsolutions.

Home Medical and Nursing
Services That Support Life in
Familiar Surroundings“I want to be true to myself and live in familiar
surroundings.” In response to such needs, Care’x
provides home medical care and nursing services. We
provide total support for users, with a focus on homevisit nursing, where nurses visit individuals’ homes toprovide various types of care. We also offer in-homecare support and operate home nursing care services.
In recent years, we have started expanding our services
to meet the growing demand for more comprehensive
care, including services not covered by insurance.
Main company

Main company

H.U. Group Corporate Profile

11

Creating innovation through integrated R&D activities
R&D

Please scan for
more details

Research and Development

The H.U. Group is constantly looking ahead to the medical and healthcare
needs of the future and engaged in R&D to provide new value.
To complement the technological and development capabilities in

Promoting technology development for nextgeneration medical treatment and healthcare

laboratory testing and diagnostics that we have accumulated since

The medical and healthcare environment is changing rapidly andour foundation, in 2017 we established H.U. Group Research Institutebecoming increasingly complex due to factors such as the advent ofG.K. (HRI). Since then we have worked to generate innovation

personalized medicine, advances in digitalization and AI technology,

through a diverse range of activities not bound by conventional

and the restricted access to medical care following the outbreak of

approaches to R&D.

the pandemic. The H.U. Group will put in place human resources
and technology platforms to enable a swift response to these major

Strengthening the Group’s R&D
capabilities and the systemchanges in the operating environment. To lead the change within
the industry, we are also actively promoting R&D activity and humanresource development across a diverse range of research fields.

In fiscal 2020, we established the Research and Development

By also actively promoting mergers and acquisitions, business

Strategy Division to drive the Group-wide integration of our R&D

alliances, and open innovation, and by utilizing and adopting thefunctions. While the R&D departments of each business and HRItechnology and business platforms of universities, medical andpursue their respective activities, the Research and Development

research institutions, enterprises, and other external organizations

Strategy Division promotes and strengthens organic Group-wide

in Japan and overseas, we aim to bring to market products andcollaboration in strategy, issues, resources, and other areas toservices of value in the shortest time possible.

drive new value creation based on Group strengths.
The R&D division of the IVD business has built a solid technology

H.U. Group R&D system

platform in diagnostic reagent development, while the R&D
division of the LTS business has know-how in new technology
evaluation and introduction. By further strengthening andleveraging these abilities, we will be in a position to rapidly develop
and bring to market highly distinctive new products. Meanwhile,
adopting diverse new technologies at an early stage, mainly
through HRI, will enable us to engage in product and service
development in new technologies and new fields. We believethat this will allow our technology platforms to make still greater

12

contributions to society, medical treatment, and healthcare.

● Development of
diagnostic reagents● Development of
unique and marketleading products● Development ofinnovative analysis
technology

Researchand Development
Strategy Division
Sharing of strategies,
technologies, andresources evelopment and●D
introduction of new tests● Promotion of
AI technology andmechanization

H.U. Group Research Institute● Technology platforms● Medical AI/big data
● Group collaboration/
human resource development

Innovation through R&D collaboration

Main company

H.U. Bioness Complex: H.U. Group’s Core Facility
Symbol of H.U. Group’s Mission to “Create New Value in Healthcare”

Please scan for
more details

The H.U. Group’s core facility, the H.U. Bioness Complex, houses cutting-edge clinical testing laboratories
capable of processing hundreds of thousands of tests a day, R&D facilities for creating innovation, a large
hall that can accommodate approximately 200 people with a simultaneous interpretation booth, and more.
The facility’s concepts are to “Connect”, “Show”, and “Nurture”.
Bioness is a hub for value creation for the benefit of human life. Where people with knowledge andexpertise can connect with one another, share information and technology, and nurture new co-creation in
health care.

Connec t

S h ow

NurtureConnect to the future withShow the world our advanced

Nurture employees with well-state-of-the-art technology

laboratory

equipped wellness facilities

●

●

●

Connect with the worldShow the potential of a safe andNurture a healthy corporate

through collaboration

efficient research facility

culture●●Connect people in an open

Show the world our

spacestate-of-the-art complex“Never Stop Testing”: BCP measures
We are strengthening our BCP measures so that

Installation of
emergency generators

Installation of watertanks in the Testing
Laboratory building

Seismically baseisolated structure:
Testing Laboratory and
R&D buildings

Earthquake resistant
structure:
Administration andWelfare buildings

our operations can continue even in the event of
a disaster. As a result, the Laboratory and R&D
buildings are able to continue operations for threedays (72 hours) even after a major earthquake.

Facility overview
Location: Akiruno City, Tokyo, Japan

Site area: Approx. 122,000 m²

Floor area : Approx. 66,000 m² (Total area of Testing
Laboratory, R&D, Administration and Welfare buildings)

H.U. Group Corporate Profile

13

The H.U. Group’s Global Expansion

Please scan for
more details

Regarding In-Vitro Diagnostics business, the H.U. Group
provides a wide range of products and services withlocations in over 100 countries throughout the world,
including some in the United States, Europe, and Asia. We
are accelerating our global expansion to provide optimal
health care to people around the world.

Sagamihara Plant, Fujirebio Inc.

EuropeJapan
United States

Fujirebio Europe N.V. 〈Belgium〉
Fujirebio Diagnostics, Inc. 〈US〉

14

Our Sustainability

Please scan for
more details

Our Approach to Sustainability
The H.U. Group Management Philosophy consists of three main declarations: Mission, Vision, and Values. We believe we can fulfill oursustainability through our business activities, which we base on our management philosophy. By means of this framework, we createstrong relationships with a wide range of stakeholders, engaging in initiatives to solve social issues through our business activities.

Our Sustainability Roadmap
The H.U. Group has announced KPIs (key performance indicators) and targets related to sustainability
efforts in the form of our Sustainability Roadmap, which follows H.U.’s Medium-term Plan: H.U. 2025. We arecontinuing to strengthen our sustainability efforts.

Contributions to SDGs
Since 1950, when our company was established as
Fujizoki Pharmaceutical, the H.U. Group has been

Two-Year Targets (FY2023–2024)

contributing to solving various social issues, including
E nv i r o n m e nt a l

E● CO 2 emissions: -12.6% (base: FY2021)

the spread of infectious diseases. Going forward, we● Waste plastic recycling rate: 82%

will continue to contribute to SDGs through realizing
sustainability via our corporate activities and through● Percentage of female managers: 22%

social infrastructure essential for supporting medical● Percentage of male employees taking parental leave: 90%● Percentage of employees answering “Satisfied with my jobs” to the questionnaire: 55%

Soc ia lS● Maintaining White 500 status● Average annual training*

1

care.
SDGs we are focusing on:time per employee: Over 30 hours● Excellent response rate (A) on UNGC Self Assessment tool: 75%*2

● Meetings with our suppliers to exchange opinions on sustainability: 30 companies*

2*1 Including DX trainings*2 FY2022–FY2024

G ove r n a nce

G● Incorporation of non-financial indicators into compensation for directors and executive

officers● Internal directors will not have a dual role on the Nominating Committee

H.U. Group Corporate Profile

15

C ORPO RAT E P ROFILEThe H.U. Group’s
official homepage

Corporate name

H.U. Group Holdings, Inc.

Headquarters

Akasaka Intercity AIR, 1-8-1, Akasaka, Minato-ku,
Tokyo 107-0052, Japan
TEL: +81-3-6279-0801 (switchboard number)
Representative: Shigekazu Takeuchi,
Director, Chairman, President and Group CEO

Foundation

December 18, 1950

Capital stock

9,279 million yen (as of March 31,2024)

Permanent employees

5,295 (Consolidated) (as of March 31,2024)

Listed stock market

Tokyo Stock Exchange, Prime Market (Stock Code: 4544)

Management structure

Company with three committees under the Companies Act of Japan

Main subsidiaries

SRL, Inc., Fujirebio Inc. and Nihon Stery, Inc.

For more details on

For more details on

Group companies

Directors & Officers

H.U. Group Holdings, Inc.
https://www.hugp.com
Date of publication: June 2024

Printed in Japan